Safety and single-dose pharmacokinetics of abacavir (1592U89) in human immunodeficiency virus type 1-infected children

Antimicrobial Agents and Chemotherapy

Volumn 43, Issue 3, 1999, Pages 609-615

  Hughes, Walter ^a   McDowell, James A ^b   Shenep, Jerry ^a   Flynn, Patricia ^a   Kline, Mark W ^c   Yogev, Ram ^d   Symonds, William ^b   Lou, Yu ^b   Hetherington, Seth ^b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b GLAXOSMITHKLINE   (United States)

^c TEXAS CHILDREN S HOSPITAL   (United States)

^d CHILDREN'S MEMORIAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADOLESCENT; AREA UNDER THE CURVE; ARTICLE; CHILD; CHILDHOOD DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; MALE; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH;

EID: 0033011805     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.43.3.609     Document Type: Article

References (22)

1. Balis, F. M., P. A. Pizzo, R. F. Murphy, J. Eddy, P. F. Jarosinski, J. Falloon, S. Broder, and D. G. Poplack. 1989. The pharmacokinetics of zidovudine administered by continuous infusion in children. Ann. Intern. Med. 110:279-285.
2. Balis, F. M., P. A. Pizzo, J. Eddy, C. Wilfert, R. McKinney, G. Scott, R. F. Murphy, P. F. Jaroninski, J. Falloon, and D. G. Poplack. 1989. Pharmacokinetics of zidovudine administered intravenously and orally in children with human immunodeficiency virus infection. J. Pediatr. 114:880-884.
3. Balis, F. M., P. A. Pizzo, K. M. Butler, M. E. Hawkins, P. Brouwers, R. N. Husson, F. Jacobsen, S. M. Blaney, J. Gress, P. Jaronski, and D. G. Poplack. 1992. Clinical pharmacology of 2′,3′-dideoxyinosinc in human immunodeficiency virus-infected children. J. Infect. Dis. 165:99-104.
4. Boucher, F. D., J. F. Modlin, S. Weller, A. Ruff, M. Mirochnick, S. Pelton, C. Wilfert, R. McKinney, M. J. Crain, M. M. Elkins, M. R. Blum, and C. G. Prober. 1993. Phase I evaluation of zidovudine administered to infants exposed at birth to the human immunodeficiency virus. J. Pediatr. 122:137-144.
5. Centers for Disease Control and Prevention. 1994. Classification system for HIV infection in children under 13 years of age. Official authorized addenda: human immunodeficiency virus infection codes and official guidelines for coding and reporting ICD-9-M. Morbid. Mortal. Weekly Rep. 43(No. RR-12):1-19.
6. Chadwick, E. G., L. A. Nazareno, T. J. Nieuwenhuis, J. W. Massarella, S. R. K. de Dennis, K. Williams, and R. Yogev, 1995. Phase 1 evaluation of zalcitabine administered to human immunodeficiency virus-infected children. J. Infect. Dis. 172:1475-1479.
7. Ching, S. V., K. M. Ayers, R. E. Dornsife, G. L. Grebe, and J. L. Howard. 1994. Nonclinical toxicology and in vitro toxicity studies with the novel anti-HIV agent (1S,4R)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol (1592U89) succinate, abstr. 188, p. 92. In Abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology. Washington. D.C.
8. Conover, W. J. 1980. Some methods based on ranks, p. 213-343. In Practical nonparametric statistics, 2nd ed. John Wiley & Sons. Inc., New York, N.Y.
9. Daluge, S. M., S. S. Good, M. B. Faletto, W. H. Miller, M. H. St. Clair, L. R. Boone, M. Tisdale, N. R. Parry, J. E. Reardon, R. E. Dornsife, D. R. Averett, and T. A. Krenitsky. 1997. 1592U89, a novel carbocyclic nucleoside analog with potent, selective anti-human immunodeficiency virus activity. Antimicrob. Agents Chemother. 41:1082-1093.
10. Davis, S. F., R. H. Beyers, M. L. Lindegren, M. B. Caldwell, J. M. Karon, and M. Gwinn. 1995. Prevalence and incidence of vertically acquired HIV infection in the United States. JAMA 274:952-955.
11. Faletto, M. B., W. H. Miller, E. P. Garvey, M. H. St. Clair, S. M. Daluge, and S. S. Good. 1997. Unique intracellular activation of the potent anti-human immunodeficiency virus agent 1592U89. Antimicrob. Agents Chemother. 41:1099-1107.
12. Good, S. S., B. X. Owens, M. B. Faletto, W. B. Mahony, and B. A. Domin. 1994. Disposition in monkeys and mice of (1S.4R)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol (1592U89) succinate. a potent inhibitor of HIV. abstr. 186, p. 92. In Abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
13. Good, S. S., S. M. Daluge, S. V. Ching, M. M. Ayers, W. B. Mahony, M. B. Falletto, B. A. Domin, B. S. Owens, R. E. Dornsife, J. A. McDowell, S. W. LaFon, and W. T. Symonds. 1995. 1592U89 succinate-preclinical toxicological and disposition studies and preliminary clinical pharmacokinetics. Antivir. Res 26:A229.
14. Hughes, W., J. McDowell, L. Adams, P. Flynn, S. Hetherington, M. Kline, J. Shenep, R. Yogev, and S. LaFon. 1996. Evaluation of the novel nucleoside 1592U89 in a phase I safety and pharmacokinetics (PK) study in HIV-infected infants and children, abstr. 195, p. 115. In Abstracts of the 3rd Conference on Retroviruses and Opportunistic Infections. Infectious Diseases Society of American for the Foundation for Retrovirology and Human Health. Alexandria, Va.
15. Kline, M. W., L. M. Dunkle, J. A. Church, J. C. Goldsmith, A. T. Harris, M. E. Federici, M. E. Schultze, L. Woods, D. F. Loewen, S. Kaul, A. Cross, V. L. Rutkiewicz, H. M. Rosenblatt, I. C. Hanson, and W. T. Shearer. 1995. A phase I/II evaluation of stavudinc (d4T) in children with human immunodeficiency virus infection. Pediatrics 96:247-252.
16. Kumar, P. N., D. E. Sweet, J. A. McDowell, W. Symonds, Y. Lou, S. Hetherington, and S. LaFon. 1991. Safety and pharmacokinetics of abacavir (1592U89) following oral administration of escalating single doses in human immunodeficiency type 1-infected adults. Antimicrob. Agents Chemother. 43:603-608.
17. Lewis, L. L., D. Venzon, J. Church, M. Farley, S. Wheeler, A. Keller, M. Rubin, G. Yuen, B. Mueller, M. Sloas, L. Wood, F. Balis, G. M. Shearer, P. Brouwers, J. Goldsmith, P. A. Pizzo, and the National Cancer Institute Pediatric Branch Human Immunodeficiency Virus Working Group. 1996. Lamvidine in children with human immunodeficiency virus infection: a phase I/II study. J. Infect. Dis. 174:16-25.
18. Pizzo, P. A., and C. Wilfert. 1994. Antiretroviral therapy for infection due to human immunodeficiency virus in children. Clin. Infect. Dis. 19:177-196.
19. Rogers, M. F. Epidemiology of HIV/AIDS in women and children in the USA. 1997. Acta Paediatr. suppl. 421:15-16.
20. Schwartz, G. J., G. B. Haycock, C. M. Edelmann, and A. Spitzer. 1976. A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine. Pediatrics 58:259-263.
21. St. Clair, M. H., J. Millard, J. Rooney, M. Tisdale, N. Parry, B. M. Sadler, M. R. Blum, and G. Painter. 1996. In vitro antiviral activity of 141W94 (VX-478) in combination with other antiretroviral agents. Antivir. Res. 29: 53-56.
22. Tisdale, M., T. Alnadaf, and D. Consens. 1997. Combination of mutations in human immunodeficiency virus type 1 reverse transcriptase required for resistance to the carbocyclic nucleoside 1592U89. Antimicrob. Agents Chemother. 41:1094-1098.